Advanced search

Filters

Country

All countries

North America

South America

Europe

Africa

Middle East

Asia

Oceania

Central America

Select all

Capitalization

Sector

All sectors

  Energy

  Basic Materials

  Industrials

  Consumer Cyclicals

  Consumer Non-Cyclicals

  Financials

  Healthcare

  Technology

  Utilities

  Real Estate

  Institutions, Associations & Organizations

  Government Activity

  Academic & Educational Services

Select all

Add a keyword

Announcement Date

Since

Until

330 Results

Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Biogen beats quarterly profit estimates, Alzheimer's drug sales jump
RE
Eisai Completes Submission of LEQEMBI® (lecanemab-irmb) Supplemental Biologics License Application for IV Maintenance Dosing for the Treatment of Early Alzheimer's Disease to the U.S. FDA
PR
Biogen expects to return to profit growth this year
RE
Biogen fourth-quarter profit misses on Aduhelm exit costs
RE
Biogen to Realign Resources for Alzheimer's Disease Franchise
GL
Biogen to Realign Resources for Alzheimer's Disease Franchise
AQ
Biogen : to Participate in the 42nd Annual J.P. Morgan Healthcare Conference
PU
"LEQEMBI Intravenous Infusion"Lecanemab) for the Treatment of Alzheimer's Disease to be Launched in Japan on December 20
AQ
Biogen : “LEQEMBI® Intravenous Infusion” (Lecanemab) for the Treatment of Alzheimer’s Disease to be Launched in Japan on December 20
PU
Biogen : Q3 2023 Biogen Earnings Presentation
PU
Biogen : Reports Q3 2023 Earnings
PU
Biogen cuts annual profit forecast on persistent higher costs
RE
EISAI PRESENTS NEW LEQEMBI INVESTIGATIONAL SUBCUTANEOUS FORMULATION INTERIM STUDY RESULTS AND CLINICAL IMPROVEMENT DATA IN EARLIER STAGES OF EARLY ALZHEIMER'S DISEASE FROM ADDITIONAL ANALYSES OF CLARITY AD
AQ
Eisai Presents New LEQEMBI® (lecanemab-irmb) Investigational Subcutaneous Formulation Interim Study Results and Clinical Improvement Data in Earlier Stages of Early Alzheimer’s Disease From Additional Analyses of Clarity AD at The Clinical Trials On Alzheimer’s Disease (CTAD) Conference
GL
EISAI PRESENTS NEW LEQEMBI® (LECANEMAB-IRMB) INVESTIGATIONAL SUBCUTANEOUS FORMULATION INTERIM STUDY RESULTS AND CLINICAL IMPROVEMENT DATA IN EARLIER STAGES OF EARLY ALZHEIMER'S DISEASE FROM ADDITIONAL ANALYSES OF CLARITY AD AT THE CLINICAL TRIALS ON ALZHEIMER'S DISEASE (CTAD) CONFERENCE
PR
Eisai Co., Ltd. - LEQEMBI Intravenous Infusion Approved for the Treatment of Alzheimer's disease in Japan
AQ
Biogen Completes Acquisition of Reata Pharmaceuticals
GL
Biogen Completes Acquisition of Reata Pharmaceuticals
AQ
"LEQEMBI Intravenous Infusion" (Lecanemab) Approved for the Treatment of Alzheimer's Disease in Japan
AQ
LEQEMBI® Intravenous Infusion (Lecanemab) Approved for the Treatment of Alzheimer’s Disease in Japan
GL
STATEMENT: BIOGEN PROVIDES UPDATE ON THE ACQUISITION OF REATA PHARMACEUTICALS
PU
Biogen Inc. Announces the Appointment of Jane Grogan, Ph.D., as Executive Vice President, Head of Research Effective 2 October 2023
CI
Biogen Appoints Jane Grogan as Head of Research
GL
Biogen Appoints Jane Grogan as Head of Research
AQ
Biogen : to Participate in the Morgan Stanley 21st Annual Global Healthcare Conference
PU
First oral medicine for postpartum depression approved
AQ
Sage Therapeutics - FDA Approves ZURZUVAE, the First and Only Oral Treatment Approved for Women with Postpartum Depression, and Issues a Complete Response Letter for Major Depressive Disorder
AQ
Biogen, Sage face uphill battle with postpartum depression pill
RE
FDA Approves ZURZUVAE™ (zuranolone), the First and Only Oral Treatment Approved for Women with Postpartum Depression, and Issues a Complete Response Letter for Major Depressive Disorder
BU
FDA Approves ZURZUVAE™ (zuranolone), the First and Only Oral Treatment Approved for Women with Postpartum Depression, and Issues a Complete Response Letter for Major Depressive Disorder
AQ
FDA Approves ZURZUVAE™ (zuranolone), the First and Only Oral Treatment Approved for Women with Postpartum Depression, and Issues a Complete Response Letter for Major Depressive Disorder
GL
Reata Pharmaceuticals : VOTING AND SUPPORT AGREEMENT - Form 8-K
PU
Biogen to acquire rare disease drugmaker for $7.3b
AQ
Reata Pharmaceuticals : Announces Biogen to Acquire Reata Pharmaceuticals
PU
Biogen to bulk up rare disease treatments with $7 billion Reata acquisition
AQ
Biogen to Acquire Reata Pharmaceuticals
GL
Biogen : Reports Second Quarter 2023 Results
PU
Biogen : reports second quarter 2023 results and reaffirms full year 2023 guidance; LEQEMBI launched in the U.S - Form 8-K
PU
Biogen : Reports Q2 2023 Earnings
PU
Biogen : Q2 2023 Biogen Earnings Presentation
PU
Biogen to cut 1,000 jobs to save costs as Alzheimer's drug launch gathers pace
RE
EISAI PRESENTS LATEST ANALYSIS OF LECANEMAB'S EFFECT ON BIOMARKER CHANGES AND SUBCUTANEOUS DOSING AT THE ALZHEIMER'S ASSOCIATION INTERNATIONAL CONFERENCE 2023
AQ
Eisai Presents Latest Analysis of Lecanemab's Effect on Biomarker Changes and Subcutaneous Dosing at The Alzheimer's Association International Conference (AAIC) 2023
PR
Eisai Presents Latest Analysis of Lecanemab’s Effect on Biomarker Changes and Subcutaneous Dosing at The Alzheimer’s Association International Conference (AAIC) 2023
GL
EISAI - FDA GRANTS TRADITIONAL APPROVAL FOR LEQEMBI FOR THE TREATMENT OF ALZHEIMER'S DISEASE
AQ
FDA Grants Traditional Approval for LEQEMBI® (lecanemab-irmb) for the Treatment of Alzheimer’s Disease
GL
FDA Grants Traditional Approval for LEQEMBI® (lecanemab-irmb) for the Treatment of Alzheimer’s Disease
AQ
Biogen Announces Changes to Its Board of Directors
GL
Biogen Announces Changes to Its Board of Directors
AQ
FDA Advisory Committee Votes Unanimously to Confirm the Clinical Benefit of LEQEMBI® (lecanemab-irmb) for the Treatment of Alzheimer's Disease
PR
No results for this search
  1. Stock Market
  2. Advanced search
  3. Christopher Viehbacher
  4. News